Aptamer Group PLC Material Agreement with Genetic Medicines Company (7178W)
December 14 2023 - 1:00AM
UK Regulatory
TIDMAPTA
RNS Number : 7178W
Aptamer Group PLC
14 December 2023
14 December 2023
Aptamer Group plc
("Aptamer", the "Company" or the "Group")
Aptamer Group signs material agreement with genetic medicines
company
- Optimer binders will be developed to support targeted genetic
medicines to specific cell types
- Contract comprises up to GBP553k in development fees for Aptamer Group
Aptamer Group plc (AIM: APTA), the developer of novel Optimer
(R) binders to enable innovation in the life sciences industry,
announces that it has entered into a material agreement with a
biotechnology company developing genetic medicines .
Under the terms of the agreement, Aptamer Group will use its
proprietary platform to discover Optimer binders to enable the
specific targeting of genetic medicines to specific cell types.
Aptamer Group will receive up to GBP553,000 in development fees for
discovering and developing the Optimer binders. Work is expected to
commence shortly subject to receiving target materials from the
customer and is expected to be completed within the current
financial year.
Optimer binders are a novel class of molecules for selectively
targeting new biomarkers and tissues. Optimers are fully synthetic
oligonucleotide molecules that offer a controlled development
process, delivering high affinity and highly selective binders,
which makes them attractive candidate molecules for drug delivery.
The smaller size of Optimers allows for improved tissue
penetration, enabling effective therapeutic delivery, while the
ability to control Optimer conjugation to therapeutic payloads
allows precision in therapeutic development and dosing of
payloads.
Dr Arron Tolley, Chief Technical Officer of Aptamer Group, said:
"This project builds on the work we have been doing in drug
delivery since being refunded and supports the need for new
delivery modalities within the genetic medicines space. Targeting
oligonucleotide therapeutics beyond hepatocytes remains a challenge
across the industry; we believe the properties of Optimers make
them suitable for developing precision-guided therapies and that
Optimer-targeted therapies may represent the next stage in targeted
drug delivery."
- ENDS -
For further information, please contact:
Aptamer Group plc
Steve Hull +44 (0) 1904 217 404
SPARK Advisory Partners Limited - Nominated
Adviser
Andrew Emmott / Mark Brady / Adam Dawes +44 (0) 20 3368 3550
-----------------------
T urner Pope I nvestments (TPI) Limited
- B roker
J ames Pope / Andrew Thacker +44 (0) 20 36 57 0 050
-----------------------
About Aptamer Group plc
Aptamer Group develops custom affinity binders through its
proprietary Optimer (R) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company
strives to deliver transformational solutions that meet the needs
of life science researchers and developers.
Optimer binders are oligonucleotide affinity ligands that can
function as an antibody alternative. The global affinity ligand
market is currently worth over $170 billion.
Aptamer has successfully delivered projects for a range of
global pharma companies, diagnostic development companies, and
research institutes, covering multiple application areas with the
objective of establishing royalty-bearing licenses.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
AGRGZMMZZFGGFZZ
(END) Dow Jones Newswires
December 14, 2023 02:00 ET (07:00 GMT)
Aptamer (LSE:APTA)
Historical Stock Chart
From Apr 2024 to May 2024
Aptamer (LSE:APTA)
Historical Stock Chart
From May 2023 to May 2024